Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 30;10(4):e00029. doi: 10.14309/ctg.0000000000000029

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 3. — Performance of the best plasma miRNA signature to discriminate between patients with pancreatic neoplasia and control individuals in our plasma set. (a) Receiver operating characteristic curve of the top miRNA signature “miR-33a-3p+miR-320a” to detect pancreatic neoplasia (PDAC or IPMN). Results are obtained from miRNA analysis by qRT-PCR in PDAC or IPMN (n = 113) and C (n = 51) plasma samples. CA19.9 diagnostic performance for patients with pancreatic neoplasia and its combination with the above-mentioned miRNA signature are also shown. (b) Scatter graph according to the scaled values of miR-33a-3p, miR-320a, and CA19.9 for PDAC, IPMN, and C plasma set (n = 182). (c) Probabilistic sensitivity analysis according to the plasma signature “miR-33a-3p+miR-320a+CA19.9.” AUC, area under the curve; C, control; IPMN, intraductal papillary mucinous neoplasm; PDAC, pancreatic ductal adenocarcinoma.